

## Special Issue

# Early-Stage Non-Small Cell Lung Cancer: Diagnostic Challenges and Therapeutic Innovations

### Message from the Guest Editors

Early-stage non-small cell lung cancer (NSCLC) presents persistent diagnostic complexity despite advances in imaging and screening. Low-dose computed tomography (LDCT) has improved detection rates, yet differentiating indolent lesions from aggressive tumours remains a challenge. Radiologic features alone are often insufficient, necessitating the integration of PET-CT, image-guided biopsy, and, increasingly, liquid biopsy and molecular profiling for accurate characterisation. Therapeutically, the landscape has evolved rapidly. Lobectomy via minimally invasive approaches remains the standard for operable patients, while stereotactic ablative radiotherapy (SABR) provides excellent local control (>90%) in those deemed medically inoperable. Precision oncology is now central to treatment planning. The integration of genomic and immunologic biomarkers informs both prognostication and therapeutic selection. Current clinical trials aim to refine neoadjuvant and adjuvant strategies, with a focus on ctDNA as a tool for minimal residual disease detection and recurrence risk stratification.

---

### Guest Editors

Dr. Efimia Boutsikou  
Dr. Georgia F. Hardavella  
Dr. Kelly Domvri

---

### Deadline for manuscript submissions

closed (15 March 2026)



## Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/248557](https://mdpi.com/si/248557)

*Journal of Clinical Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcm@mdpi.com](mailto:jcm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm)





# Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm.mdpi.com/)



## About the Journal

### Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

---

### Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67081  
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, The University of  
Tokyo, Tokyo, Japan

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.5 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).